<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01030042</url>
  </required_header>
  <id_info>
    <org_study_id>2007-006254-26</org_study_id>
    <nct_id>NCT01030042</nct_id>
  </id_info>
  <brief_title>Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients</brief_title>
  <acronym>COMETS</acronym>
  <official_title>Randomized, Phase III, Multicenter Trial Comparing Two Different Sequences of therapyFOLFOX-4 vs FOLFOX-4 Followed by Irinotecan/Cetuximab in Metastatic Colorectal Patients Treated With FOLFIRI /Bevacizumab as First Line Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:

      Aim of this study is to compare the efficacy and safety of two different sequences of
      chemotherapeutic agents in order to optimize the treatment of patients with metastatic
      colorectal cancer progressed to a first line chemotherapy with FOLFIRI and bevacizumab.
      Primary endpoint will be overall survival, defined as the time elapsed from the date of
      randomization to the date of patient death due to any cause, or the last date the patient was
      known to be alive.

      Secondary Objectives Progression free survival, Quality of life, Health resource utilisation
      and economic evaluation, Toxicity and incidence of adverse events

      The study regimen includes:

      Strategy A: FOLFOX-4 followed, after progression, by irinotecan/cetuximab Strategy B:
      irinotecan/cetuximab followed, after progression, by FOLFOX-4 Patients will be randomly
      assigned to one of the two treatment sequences (with 1:1 ratio) using a block design
      randomization procedure stratified according to center.

      The patient accrual period is planned for approximately 36 months. To assess OS, all pts will
      be followed for up to 18 months after the last patient is randomised. The maximum estimated
      study duration is approximately 54 months.All statistical analyses will be based on an
      intention-to-treat approach. CONSORT rules will be applied to describe study flow and
      protocol deviations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target population:

      Patients with histologically confirmed metastatic colorectal cancer progressed after a first
      line treatment containing FOLFIRI and BEV

      Inclusion criteria:

        -  Age &gt;18 &lt; 75 years of age

        -  Diagnosis of histologically proven adenocarcinoma of the colon or rectum, stage IV

        -  K-ras wild-type

        -  ECOG performance status 0-1 at study entry

      Endpoints:

      - Response Rate, Disease control rate, The duration of overall response, Overall survival,
      PFS, Time to treatment failure, Quality of Life, Incidence of AEs, Frequency and nature of
      serious adverse reactions (SADRs), Premature withdrawals

      Statistical methods:

      Assuming a randomization ratio of 1:1, 282 deaths are required in order to achieve a power of
      80% of detecting a hazard ratio of 0.72 in favour of one of the two sequences, translating in
      an increase of median survival time from 10 to 14 months, with a type I error of 5%,
      two-sided, using the Mantel-Cox version of the log-rank test. With a uniform accrual period
      of 3 years and a follow-up of 18 months, about 350 patients will be needed to reach the
      target number of events.

      All statistical analyses will be based on an intention-to-treat approach. CONSORT rules will
      be applied to describe study flow and protocol deviations.

      All OS and PFS curves will be drawn with the Kaplan-Meier method. Results will be presented
      as Hazard Ratio (HRs) and their 95% Confidence Interval (CIs).

      On annual basis, starting from the second year, an interim analysis will be conducted. In
      principle, no formal stopping rule will be applied, unless otherwise suggested by the DSMC.
      Safety reports will be drawn on annual basis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>the time from the date of randomisation to the date of death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>the time relapsed from the date of randomization and the date of progression after third-line treatment or death</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab/Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab/irinotecan followed, after progression, by FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFOX 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FOLFOX-4 (Oxaliplatin, leucovorin and 5-fluorouracil) followed, after progression, by irinotecan/cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX-4</intervention_name>
    <description>Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).</description>
    <arm_group_label>FOLFOX 4</arm_group_label>
    <other_name>Oxaliplatin, 5FU, Leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan/Cetuximab</intervention_name>
    <description>CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.
IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression.</description>
    <arm_group_label>Cetuximab/Irinotecan</arm_group_label>
    <other_name>CPT11/Cetuximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 &lt;75 years of age

          -  Diagnosis of histologically proven adenocarcinoma of the colon or rectum, stage IV

          -  K-ras wild-type

          -  Performance Status (ECOG-PS) 0-1 at study entry

          -  Neutrophils ≥ 1.5 x 1039/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL

          -  Bilirubin level either normal or &lt; 1.5 x upper limit of normal (ULN)

          -  Asparagine aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤ 2.5 X ULN (≤
             5 x ULN if liver metastasis are present)

          -  Serum creatinine &lt; 1.5 x ULN

          -  Effective contraception for both male and female patients

          -  Life expectancy of ≥ 3 months

          -  Signed written informed consent

        Exclusion Criteria:

          -  History or presence of other disease, metabolic dysfunction, physical examination
             finding, or clinical laboratory finding giving reasonable suspicion of a disease or
             condition that contraindicates use of an investigational drug or patient at high risk
             from treatment complications

          -  Other malignancies within the last 5 years (other than curatively treated basal cell
             carcinoma of the skin and/or in situ carcinoma of the cervix)

          -  History of psychiatric disability judged by the investigator to be clinically
             significant, precluding informed consent or interfering with compliance for oral drug
             intake

          -  Known grade 3 or 4 allergic reaction to any of the components of the treatment

          -  Known drug abuse/ alcohol abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale Profili</name>
      <address>
        <city>Fabriano</city>
        <state>AN</state>
        <zip>60044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usl 11 Ospedale Murri</name>
      <address>
        <city>Fermo</city>
        <state>AP</state>
        <zip>63023</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio, P.le Ospedale n1</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spedali Civili</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Lanciano-Vasto</name>
      <address>
        <city>Lanciano</city>
        <state>CH</state>
        <zip>66034</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico del Mediterraneo</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL 11</name>
      <address>
        <city>Empoli</city>
        <state>FI</state>
        <zip>50010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Maggiore</name>
      <address>
        <city>Lodi</city>
        <state>LO</state>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S.Vincenzo</name>
      <address>
        <city>Taormina</city>
        <state>ME</state>
        <zip>98039</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Serbelloni</name>
      <address>
        <city>Gorgonzola</city>
        <state>MI</state>
        <zip>20064</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ricerca S.Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MI</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Salvatore</name>
      <address>
        <city>Pesaro</city>
        <state>PS</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Urbino</city>
        <state>PS</state>
        <zip>61029</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Carlo</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AULSS 18 di Rovigo</name>
      <address>
        <city>Rovigo</city>
        <state>RO</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Morelli</name>
      <address>
        <city>Sondalo</city>
        <state>SO</state>
        <zip>23100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Mater Salutis</name>
      <address>
        <city>Legnago</city>
        <state>VR</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Umberto I - Università - Località Torretta</name>
      <address>
        <city>Ancona</city>
        <zip>60020</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti, Largo Barozzi, 1</name>
      <address>
        <city>Bergamo</city>
        <zip>24128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Poliambulanza, Via Bissolati 57</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale S.Anna</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Carlo Poma - Via Albertoni, 1</name>
      <address>
        <city>Mantova</city>
        <zip>46100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori - Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Campus Biomedico, Via Emilio Longoni, 83</name>
      <address>
        <city>Roma</city>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. S.Giovanni Calabita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2009</study_first_submitted>
  <study_first_submitted_qc>December 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2009</study_first_posted>
  <last_update_submitted>July 14, 2015</last_update_submitted>
  <last_update_submitted_qc>July 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>two sequences therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

